×
0 0 0 -0.0384615384615385 -0.0384615384615385 -0.0673076923076922 -0.076923076923077 -0.0736153846153845
Stockreport

Kedrion Biopharma and Kamada receive FDA approval of KEDRAB for post-exposure prophylaxis against rabies infection; shares ahead 21% premarket [Seeking Alpha]

KAMADA LTD (KMDA)  More Company Research Source: Seeking Alpha
Last kamada ltd earnings: 11/13 06:30 am Check Earnings Report
PDF </header> ACORN:3101766306 Kedrion Biopharma and NASDAQ-NMS:KMDA Kamada (NASDAQ: KMDA ) announces that KEDRAB [rabies immune globulin (Human)] has received FDA approval for passive, transient post-exposure prophylaxis of rabies infection, [Read more]

IMPACT SNAPSHOT EVENT TIME: KMDA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

-10.58%

KMDA's stock displays remarkable fall of -10.58% from 5.20-share to 4.65-share since news

EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS